| P2093 | author name string | Montpetit A | |
| | Sotgiu S | |
| | Sadovnick AD | |
| | Hudson TJ | |
| | Risch NJ | |
| | Chao M | |
| | Ebers GC | |
| | Dyment DA | |
| | Pugliatti M | |
| | DeLuca GC | |
| | Herrera BM | |
| | Ramagopalan SV | |
| | Barnardo MC | |
| | Lincoln MR | |
| P2860 | cites work | PedCheck: a program for identification of genotype incompatibilities in linkage analysis | Q24539016 |
| | HLA-DR patterns in pernicious anaemia | Q24551014 |
| | The structure of haplotype blocks in the human genome | Q27860500 |
| | Haploview: analysis and visualization of LD and haplotype maps | Q27860955 |
| | Major histocompatibility complex class II alleles and the course and outcome of MS: a population-based study | Q28283282 |
| | Parametric and nonparametric linkage analysis: a unified multipoint approach | Q28762162 |
| | Risk alleles for multiple sclerosis identified by a genomewide study | Q29614890 |
| | Heterogeneity of multiple sclerosis lesions: implications for the pathogenesis of demyelination | Q29614990 |
| | The inheritance of resistance alleles in multiple sclerosis | Q33298407 |
| | An immunogenetic heterogeneity in multiple sclerosis | Q33591702 |
| | HLA-DR2 dose effect on susceptibility to multiple sclerosis and influence on disease course | Q33904555 |
| | HLA-DR15 is associated with lower age at onset in multiple sclerosis | Q33913434 |
| | Extreme discordant phenotype methodology: an intuitive approach to clinical pharmacogenetics | Q34116501 |
| | Primarily chronic progressive and relapsing/remitting multiple sclerosis: two immunogenetically distinct disease entities | Q34304182 |
| | Two genes encoding immune-regulatory molecules (LAG3 and IL7R) confer susceptibility to multiple sclerosis | Q34388729 |
| | Twin concordance and sibling recurrence rates in multiple sclerosis. | Q34542659 |
| | Functional epistasis on a common MHC haplotype associated with multiple sclerosis | Q34571353 |
| | MHC class II proteins and disease: a structural perspective | Q36430136 |
| | Genetic basis of multiple sclerosis: HLA antigens, disease progression, and oligoclonal IgG in CSF | Q39566088 |
| | The multiple sclerosis- and narcolepsy-associated HLA class II haplotype includes the DRB5*0101 allele | Q41287692 |
| | Combined effect of HLA-DRB1*1501 and interleukin-1 receptor antagonist gene allele 2 in susceptibility to relapsing/remitting multiple sclerosis | Q44151233 |
| | Axonal loss in multiple sclerosis: a pathological survey of the corticospinal and sensory tracts | Q44816677 |
| | The interpretation of electromyographic responses to electrical stimulation of the motor cortex in diseases of the upper motor neurone | Q48227567 |
| | HLA-DR2 and narcolepsy | Q48974743 |
| | Autoimmune disease in families with multiple sclerosis: a population-based study. | Q51750687 |
| | HLA and prognosis in multiple sclerosis. | Q52881363 |
| | HL-A antigens and multiple sclerosis. | Q53892212 |
| | Finding genetic modifiers of cystic fibrosis. | Q53989030 |
| | Genetics of multiple sclerosis | Q54114782 |
| | A predominant role for the HLA class II region in the association of the MHC region with multiple sclerosis | Q57310432 |
| | Complex interactions among MHC haplotypes in multiple sclerosis: susceptibility and resistance | Q57317727 |
| | B-cell alloantigen Ag 7a in multiple sclerosis | Q57464621 |
| | Microsatellites and genome scans — A GAMES postscript | Q57912330 |
| | The influence of HLA-DRB1 genes on disease severity in rheumatoid arthritis | Q67567811 |
| | Association of HLA-DR with sarcoidosis. Correlation with clinical course | Q68826805 |
| | Histocompatibility determinants in multiple sclerosis, with special reference to clinical course | Q70004581 |
| | Multiple Sclerosis: Association with HL—A3 | Q70493174 |
| | HLA and heterogeneity of multiple sclerosis | Q72046964 |
| | HLA-DRB1*0401/0404 genotype and rheumatoid arthritis: increased association in men, young age at onset, and disease severity | Q72057348 |
| | HLA profiles in multiple sclerosis suggest two forms of disease and the existence of protective haplotypes | Q72106419 |
| | Extreme discordant sib pairs for mapping quantitative trait loci in humans | Q72304785 |
| | A comparison of the pathology of primary and secondary progressive multiple sclerosis | Q72708285 |
| | Immunogenetic heterogeneity of multiple sclerosis in Sardinia | Q74625391 |
| | Canadian collaborative project on genetic susceptibility to MS, phase 2: rationale and method. Canadian Collaborative Study Group | Q77100565 |
| | A study of the HLA-DR region in clinical subgroups of multiple sclerosis and its influence on prognosis | Q78059515 |
| | Old suspects found guilty--the first genome profile of multiple sclerosis | Q80693902 |
| P433 | issue | 52 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | multiple sclerosis | Q8277 |
| P304 | page(s) | 20896-20901 | |
| P577 | publication date | 2007-12-17 | |
| P1433 | published in | Proceedings of the National Academy of Sciences of the United States of America | Q1146531 |
| P1476 | title | An extremes of outcome strategy provides evidence that multiple sclerosis severity is determined by alleles at the HLA-DRB1 locus | |
| P478 | volume | 104 | |